Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
29.18
+0.16 (0.55%)
Jan 29, 2026, 11:47 AM EST - Market open
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $9.70M in the quarter ending September 30, 2025, a decrease of -32.03%. This brings the company's revenue in the last twelve months to $55.70M, down -84.07% year-over-year. In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%.
Revenue (ttm)
$55.70M
Revenue Growth
-84.07%
P/S Ratio
48.91
Revenue / Employee
$109,218
Employees
510
Market Cap
2.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | 18.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 578.20M |
| Tarsus Pharmaceuticals | 366.10M |
| Arcutis Biotherapeutics | 317.93M |
| Adaptive Biotechnologies | 252.75M |
| IDEAYA Biosciences | 214.83M |
| Viridian Therapeutics | 70.79M |
BEAM News
- 15 days ago - Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - Beam Therapeutics: Pivoting From Platform To Execution Stage - Seeking Alpha
- 17 days ago - Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
- 2 months ago - Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - GlobeNewsWire
- 3 months ago - Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire